Latest News and Press Releases

BASKING RIDGE, N.J. , Nov. 06, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies...

Entrada Therapeutics reports financial results for the third quarter ended September 30, 2025, and highlights recent business updates.

Aclaris Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

-- Company will host a webcast at 10am ET on November 6, 2025, to discuss its Phase 2a study to assess efficacy, safety and tolerability of BMB-101 (NOVA Study) for the treatment of patients with...

- Topline data from Registrational Expansion Cohort of DELIVER trial of zeleciment rostudirsen (z-rostudirsen, also known as DYNE-251) in DMD on track for December 2025 to support potential submission...

Austin, TX, USA, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Floor POP Display Market Size, Trends and Insights By Material Type (Corrugated...

– Presented positive data from Phase 1 clinical trials with ARV-102 in healthy volunteers and patients with Parkinson’s disease – – Presented preclinical data from ARV-806 demonstrating robust and...

FDA feedback enables CervoMed to proceed with proposed endpoints, patient enrichment strategy, and other key aspects of Phase 3 trial design to support potential New Drug Application CervoMed is...

Ascendant acquires FTNI, unifying payables and receivables to streamline domestic and cross-border payments, reduce manual work, and boost visibility.

NMRA-898 is structurally distinct from NMRA-861 and is the second M4 PAM in Neumora’s M4 franchise; both programs have potential best-in-class pharmacology No convulsions observed in pre-clinical...